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Background: Few studies have measured the burden of adult pneumococcal disease after the introduction
of 13-valent pneumococcal conjugate vaccine (PCV13) into the US infant vaccination schedule. Further,
most data regarding pneumococcal serotypes are derived from invasive pneumococcal disease (IPD),
which represents only a fraction of all adult pneumococcal disease burden. Understanding which pneu-
mococcal serotypes cause pneumonia in adults is critical for informing current immunization policy. The
objective of this study was to measure the proportion of radiographically-confirmed (CXR+) community-
acquired pneumonia (CAP) caused by PCV13 serotypes in hospitalized US adults.
Methods: This observational, prospective surveillance study recruited hospitalized adults aged 18 years
from 21 acute care hospitals across 10 geographically-dispersed cities in the United States between
October 2013 and September 2016. Clinical and demographic data were collected during hospitalization.
Vital status was ascertained 30 days after enrollment. Pneumococcal serotypes were detected via culture
from the respiratory tract and normally-sterile sites (including blood and pleural fluid). Additionally, a
novel, Luminex-based serotype-specific urinary antigen detection (UAD) assay was used to detect sero-
types included in PCV13.
Results: Of 15,572 enrolled participants, 12,055 eligible patients with CXR+CAP were included in the final
analysis population. Mean age was 64.1 years and 52.7% were aged 65 years. Common comorbidities
included chronic obstructive pulmonary disease (43.0%) and diabetes mellitus (28.6%). PCV13 serotypes
were detected in 552/12,055 (4.6%) of all patients and 265/6347 (4.2%) of those aged 65 years. Among
patients aged 18–64 years PCV13 serotypes were detected in 3.8–5.3% of patients depending on their risk
status.
Conclusions: After implementation of a pneumococcal conjugate vaccination program in US children, and
despite the herd protection observed in US adults, a persistent burden of PCV13-type CAP remains in this
population.
 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
https://doi.org/10.1016/j.vaccine.2019.04.087
0264-410X/ 2019 The Author(s). Published by Elsevier Ltd.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
Community-acquired pneumonia (CAP) is an infection of the
lung parenchyma that develops in persons outside of a health-
care facility. Pneumonia and other lower respiratory tract infec-
tions cause 79% of infectious-disease-related deaths in the
United States [1]. Adults aged 65 years have substantial mor-
bidity and mortality related to CAP [2], and are hospitalized
more frequently with the disease compared to younger popula-
tions. Comorbid conditions such as chronic respiratory disease,
chronic heart disease, diabetes mellitus, and high alcohol intake
place individuals at increased risk for CAP, more severe illness,
and worse outcomes than otherwise healthy individuals [3–5].
In addition, adults with immunocompromising conditions such
as human immunodeficiency virus (HIV) infection, chronic renal
failure, leukemia, and lymphoma are at even higher risk of
developing CAP [6].
Streptococcus pneumoniae is a leading cause of CAP, bacterial
meningitis, and bacteremia [7–13]. Non-invasive CAP is the most
common manifestation of pneumococcal disease in adults. In
2004, S. pneumoniae was estimated to be the etiologic agent in
nearly 600,000 cases of pneumonia in US adults aged >18 years
[14]. Although S. pneumoniae remains the most commonly identi-
fied cause of bacterial CAP, the estimated proportion of disease
attributed to S. pneumoniae has decreased since the introduction
of pneumococcal conjugate vaccines (PCV) for use in children
and adults [15–17].
In 2000, a 7-valent PCV (PCV7) covering serotypes 4, 6B,
9V, 14, 18C, 19F, and 23F was introduced into the US infant
vaccination program. In 2010, PCV7 was replaced with a 13-
valent PCV (PCV13) which added coverage for serotypes 1, 3,
5, 6A, 7F, and 19A. Well-documented, significant reduction of
vaccine-type pneumococcal diseases has resulted from this
vaccination program in the United States and in other
cohorts of children around the world [18–21]. Unvaccinated
children and adults have also benefited from the indirect
(herd) effects of the program [22–25]. In September 2014,
the US Centers for Disease Control and Prevention (CDC)
Advisory Committee on Immunization Practices (ACIP)
expanded their 2012 recommendation of PCV13 in adults
with immunocompromising conditions [6] to include all
adults aged 65 years [26].
The majority of data describing the prevalence of pneumo-
coccal serotypes are limited to invasive pneumococcal disease
(IPD). Culture-based diagnostic methods can only identify a
very limited fraction of VT-bacteremic pneumonia and conven-
tional urinary diagnostic testing methods (such as the Binax-
NOW assay [27]) cannot identify the specific pneumococcal
serotypes in patients with pneumonia [28]. Therefore, a novel,
proprietary urinary antigen detection (UAD) assay was devel-
oped [29] to detect 13 serotype-specific pneumococcal antigens
corresponding to the serotypes contained in PCV13 [29]. Few
studies investigating pneumococcal serotype distribution in
CAP utilizing the UAD have been completed since the introduc-
tion of PCV13 in adults [28]. Thus, the current burden of non-
invasive CAP due to PCV13 serotypes in adults is not fully
understood.
The primary objective of this study was to estimate the propor-
tion of radiographically-confirmed (CXR+) CAP caused by S. pneu-
moniae serotypes contained in PCV13 among adults aged
18 years. A secondary objective was to describe the difference
in detection of S. pneumoniae by culture, BinaxNOW, and UAD.
We also report mortality related to CXR+CAP.
2. Methods
2.1. Study design and participants
Detailed methodology for this observational, prospective study
of adults aged 18 years hospitalized with CXR+CAP has been pub-
lished previously [30]. Briefly, study participants were recruited
between October 2013 and September 2016 from 21 acute care
hospitals across 10 cities (Akron, OH, Chicago, IL, Detroit, MI, Louis-
ville, KY, Nashville, TN, Norfolk, VA, Houston TX, Las Vegas, NV, San
Diego, CA, Worcester, MA). Each city had one hospital site involved
in adult CAP patient recruitment except for Detroit, MI (n = 2), San
Diego, CA (n = 3), and Louisville, KY (n = 9). Institutional Review
Board approval was obtained from each individual institution. This
study was conducted in accordance with applicable laws and reg-
ulations including, but not limited to, the International Conference
on Harmonization Guideline for Good Clinical Practice and the eth-
ical principles of the Declaration of Helsinki. All study participants
provided informed consent prior to enrollment.
2.2. Inclusion criteria
All adults who presented to any of the study hospitals or emer-
gency departments with suspected pneumonia were prospectively
identified and screened for inclusion. Selection criteria were eval-
uated at the time of enrollment. To be eligible, participants had
to: (1) be aged 18 years; (2) present to a study healthcare facility
where the treating clinician clinically suspected CAP based on the
presence of two or more of the following signs or symptoms: fever
or hypothermia within 24 h of enrollment, chills or rigors, pleuritic
chest pain, cough, sputum production, dyspnea, tachypnea,
malaise, or abnormal auscultatory findings suggestive of pneumo-
nia; (3) have a radiographic finding confirmed by a board-certified
radiologist that was consistent with pneumonia obtained no more
than 72 h prior to study enrollment; and (4) be able and willing to
provide a urine sample.
2.3. Exclusion criteria
Participants were excluded if they had hospital-acquired pneu-
monia (HAP). HAP was defined as any patient who was i) trans-
ferred to a study healthcare facility after already being
hospitalized for 48 h at any other in-patient facility, such as a
community hospital, or ii) developed signs and symptoms of pneu-
monia after being hospitalized at a study site for 48 h. Patients
were also excluded if they had severe chronic conditions or labora-
tory abnormalities that may increase the risk associated with study
participation or may interfere with the interpretation of study
results and, in the judgment of the investigator, would make the
patient inappropriate for entry into this study. Finally, patients
who were previously enrolled in the study within the past 30 days
were also excluded. Thus, patients could contribute >1 CAP hospi-
talization event to the study if a subsequent CAP hospitalization for
the same patient occurred >30 days after the previous
hospitalization.
2.4. Risk status definitions
Participants were classified as ‘‘high-risk” if they had any of the
following immunocompromising medical conditions: chronic kid-
ney disease including end-stage renal disease (ESRD), organ trans-
plantation, immunodeficiency, hematologic cancer/malignancy,
solid tumor cancer/malignancy, acquired immunodeficiency
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syndrome (AIDS), HIV, or immunosuppressive drug therapy. Partic-
ipants were classified as ‘‘at-risk” if they did not fulfill the criteria
for ‘‘high-risk” (ie, were not immunocompromised) and had any of
the following medical conditions or health behaviors: asthma, con-
gestive heart failure, liver disease, chronic obstructive pulmonary
disease (COPD), diabetes mellitus, current smoking, or alcohol
abuse. The presence of medical conditions was determined by
medical record review, and health behaviors like smoking and
alcohol abuse were based on self-reported data obtained from a
screening questionnaire. Participants who were not categorized
as ‘‘high-risk” or ‘‘at-risk” were considered ‘‘low-risk”. These risk
categories were based on CDC designations which are applied to
current ACIP recommendations for pneumococcal vaccination
[31–33].
2.5. Study assessments
If eligible for enrollment, participant demographic and medical
history information was collected. Results of blood and respiratory
cultures collected as a part of the patient’s standard medical care
were recorded. For participants not having blood cultures collected
as standard medical care, blood was collected for culture as a
study-related procedure. Urine was collected in a non-invasive
manner from all patients as a study-related procedure as soon as
possible following the signing of the Informed Consent. When fea-
sible, urine was collected within 24 h after study enrollment. Only
patients with a final diagnosis of CXR+CAP confirmed by a study
physician were included. Hospital admission and discharge dates
were also collected. Assessment of vital status occurred up to
30 days after enrollment.
2.6. Microbiological assessments
All samples collected either as part of standard of care or
study-related procedure underwent bacterial culture at the local
laboratory for the identification of pathogens (and antibiotic sus-
ceptibility) according to standard methodology. All S. pneumoniae
isolates were sub-cultured and maintained at the study sites. An
aliquot was also sent to a central laboratory for confirmation of
S. pneumoniae and serotype identification. In addition to laboratory
culture, both BinaxNOW and the serotype-specific S. pneumoniae
UAD assay were performed on urine samples [30]. UAD and
BinaxNOW testing of urine samples was completed at Pfizer’s
Vaccines Research and Development Laboratory (Pearl River, NY).
Urine testing and serotyping were performed blinded to all clinical
information.
2.7. UAD assay
The UAD is a validated limit assay based on defined positivity
cut-off limits and can simultaneously detect the 13 different sero-
types of S. pneumoniae that are contained in PCV13 by capturing
serotype-specific polysaccharides excreted in human urine [29].
This assay has demonstrated higher sensitivity than culture or con-
ventional urinary antigen detection and excellent specificity in a
convenience sample obtained from 776 participants with CXR
+CAP [34], and in a separate prospective study of adults with
radiographically-confirmed pneumonia [17]. Co-detections of up
to two serotypes constitute a valid result and were reported.
Detection of three or more serotypes was classified as an indeter-
minate result [29].
2.8. Data analysis
Only patients who met study eligibility criteria, had a final diag-
nosis of CXR+CAP, and did not receive pneumococcal vaccine
within 30-days of study enrollment (based on patient self-report)
were included in the primary analysis population. Patients who
received a pneumococcal vaccine within 30 days of enrollment
were excluded because a previous study suggested that recent
pneumococcal vaccination could impact detection of pneumococ-
cal serotypes in urine samples [35]. Patients with S. pneumoniae
isolated from any microbiologic specimen, or with a positive
UAD assay or BinaxNOW result were considered to have S. pneumo-
niae detected. The proportion of patients in the final analysis pop-
ulation where S. pneumoniae and PCV13 serotypes were detected
was summarized using descriptive statistics. Categorical variables
were described using frequencies and percentages, and continuous
variables were described with means (with standard deviations),
ranges, and medians (for highly skewed variables). Results were
presented for the entire analysis population and were also strati-
fied across time period (ie, epidemiological year) and four different
age/risk groups that reflected current ACIP recommendations for
pneumococcal vaccination [31–33] (ie, all adults aged 65 years
and adults aged <65 years with high-risk, at-risk, or low-risk con-
ditions as described previously). Chi-square tests were used to
evaluate changes in PCV13 serotypes over time, comparing the
proportion of PCV13 serotypes identified in year one to year three,
for each age/risk group.
3. Results
Overall, 15,572 participants were enrolled, 12,055 of which
were eligible, had CXR+CAP, and were included in the final analysis
population (Table 1). Most participants (79.7%) included in the
analysis were recruited from hospitals in Louisville, KY. Roughly
half (52.7%, n = 6347) were aged 65 years, 15.5% were aged 18
to 64 years with high-risk conditions (n = 1864), 24.7% were aged
18 to 64 years with at-risk conditions (n = 2976), and 7.2% were
aged 18 to 64 years without underlying chronic illness (ie, low-
risk; n = 868) (Table 1). Mean age at consent was 64.1 years.
Roughly half (50.5%) of the participants were female and the
majority (80.0%) was white/non-Hispanic. Mean pneumonia sever-
ity index (PSI) score was 89.5, although patients aged 65 years
had a mean score of 110.2 (Table 2). Mean hospital stay was
7.1 days (supplementary Table 1).
3.1. Chronic medical conditions and risk status
In total, 38.5% and 47.8% of all patients were considered high
risk and at risk, respectively (supplementary Table 1). The most
prevalent at-risk conditions were chronic obstructive pulmonary
disease (43.0%), smoking (29.3%), and diabetes (28.6%), while the
most prevalent high-risk conditions were chronic kidney disease
(15.4%), solid tumor (15.3%), and immunosuppressant therapy
(12.4%) (supplementary Table 1). Only 13.8% (1659/12,055) did
not have at least one high-risk or at-risk condition.
3.2. S. pneumoniae detection
S. pneumoniae was detected in 1194/12,055 (9.9%) participants
as determined by BinaxNOW, UAD, or culture. S. pneumoniae was
detected by UAD alone in 345/12,055 (2.9%) patients, which repre-
sented 28.9% (345/1194) of all pneumococcal CAP detected.
Another 122/12,055 (1.0%) cases were detected by culture alone,
and 447/12,055 (3.7%) cases were detected by BinaxNOW alone
(Fig. 1). Using any diagnostic method, S. pneumoniae was detected
in 585/6347 (9.2%) of those aged 65 years and 609/5708 (10.7%)
of those aged 18 to 64 years (supplementary Table 2). For patients
aged <65 years, the prevalence of S. pneumoniae was 10.8%
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(201/1864), 11.2% (334/2976), and 8.5% (74/868), for high risk, at
risk, and low risk respectively (supplementary Table 2).
3.3. PCV13 serotype detection
Overall, PCV13 serotypes were detected in 552 of 12,055 (4.6%)
participants via UAD or culture (Table 3). Among those, PCV13 ser-
otypes were detected in 42 patients (7.6%) via culture, and 547
patients (99.1%) via UAD. Of the 547 detected by UAD, 65 (11.9%)
had two serotypes identified. Of the 37 patients where a PCV13
serotype was identified by both UAD and culture, the same sero-
type was identified in 34 patients (91.9%). The three patients with
different serotypes identified between culture and UAD were: 3
(blood culture) vs 19A (UAD); 3 (sputum culture) vs 3 and 18C
(UAD); and 3 (sputum culture) vs 5 and 9V (UAD). The five patients
who had PCV13 identified only from culture were serotypes 19F
(n = 2), 3 (n = 2), and 19A (n = 1).
Overall, the most common S. pneumoniae serotypes detected
were PCV13 serotypes not covered by PCV7 (Table 3), however, a
UAD was not available for non-PCV13 serotypes. These included
serotypes 19A (1.3%, n = 152), 3 (1.1%, n = 130), 5 (0.6%, n = 78),
7F (0.4%, n = 54), and 6A (0.4%, n = 47) (Table 2). Serotype 1, also
a PCV13 serotype not covered by PCV7, was detected at a similar
frequency to the most common PCV7 serotypes (14, 18C, 19F,
and 23F each 0.2%). The remaining PCV7 serotypes included sero-
types 4 and 9V (each 0.1%) and serotype 6B (<0.1%, n = 6) (Table 3).
Non-vaccine type S. pneumoniae (as determined by culture only)
was identified in 1.4% (n = 173) of patients. The most common
non-PCV13 serotype was 22F (0.2%, n = 28); all others occurred in
<0.1% of all participants. PCV13 serotypes were detected in
265/6347 (4.2%) participants aged 65 years. Among patients aged
18–64 years classified as high-risk, at-risk, or low-risk, PCV13 ser-
otypes were detected by UAD or culture in 95/1864 (5.1%),
159/2976 (5.3%), and 33/868 (3.8%), respectively.
Among all participants >18 years of age over the three-year
study period (October 2013 through September 2016), the propor-
tion caused by PCV13 serotypes decreased from 5.3%
(n = 163/3076) in the first year to 4.6% (n = 247/5366) and 3.9%
(n = 142/3613) in years two and three, respectively (P = .01 year
one vs year three). This statistically-significant reduction trend
was driven by reductions among adults aged 65 years (5.1%
[76/1495] at year one vs 3.4% [68/2010] at year three, P = .01)
and in high-risk patients aged 18–64 years (7.0% [37/530] at year
one vs 4.0% [17/428] at year three [n = 17], P = .05) (Fig. 2). Reduc-
tions were generally seen across all PCV13 serotypes except for
serotype 3, which did not decrease in prevalence over the study
period. Serotype-specific evaluations, however, were limited by
small sample size (supplementary Table 3). For adults aged 18–
64 years with at-risk (5.3% [41/782] at year one vs 5.3% [50/948]
at year three, P = .98) or low-risk (3.4% [9/269] at year one vs
3.1% [7/227] at year three, P = .87) conditions, the prevalence of
PCV13 serotypes remained stable over the study period (Fig. 2).
3.4. Mortality
Deaths occurring within 30 days of enrollment were recorded,
as were some deaths occurring after day 30 (due to follow-up
schedule, etc.). Overall mortality was 9.0% (1081/12,055), and
514 (47.5%) of these deaths were caused by pneumonia (Table 4).
Thirty-day mortality was 8.4% (1009/12,055) (Table 4). Overall
mortality among patients with PCV13 serotype-positive CXR+CAP
was similar to the overall study population (9.4%, 52/552), and
30 of these deaths (57.7%) were caused by pneumonia. Thirty-
day mortality among those with PCV13 serotype-positive CXR
+CAP was also similar (8.7%, 48/552) (Table 4).
Overall mortality among patients aged 18–64 years classified as
high-risk, at-risk, and low-risk was 8.8% (164/1864), 3.0%
(90/2976), and 1.6% (14/868), respectively (Table 4). As expected,
higher overall mortality (12.8%, 813/6347) was seen in patients
aged 65 years. Patients aged 65 years (11.9%, 754/6347) and
those aged 18–64 years classified as high-risk (8.4%, 156/1864)
were more likely to die within 30 days of hospitalization when
compared to adults aged <65 years with at-risk (2.9%, 85/2976)
or low-risk (1.6%, 14/868) conditions (Table 4).
Table 1
Analysis populations by age and risk condition, n = 15,572.
Age/risk group
Unknown 65n (%) 18–64 high-
risk n (%)
18–64 at-
risk n (%)
18–64 low-
risk n (%)
Total n (%)
All enrolled populationa 559 8234 (100.0%) 2210 (100.0%) 3574 (100.0%) 995 (100.0%) 15,572 (100.0%)
Radiographically confirmed CAP 6347 (77.1%) 1864 (84.3%) 2976 (83.3%) 868 (87.2%) 12,055 (77.4%)
SP + CAP subpopulation 585 (7.1%) 201 (9.1%) 334 (9.3%) 74 (7.4%) 1194 (7.7%)
SP – CAP subpopulation 5762 (70.0%) 1663 (75.2%) 2642 (73.9%) 794 (79.8%) 10,861 (69.7%)
Excluded from CAP populationb 559 1887 (22.9%) 346 (15.7%) 598 (16.7%) 127 (12.8%) 3517 (22.6%)
Important protocol deviations 558 863 (10.5%) 20 (0.9%) 20 (0.6%) 10 (1.0%) 1471 (9.4%)
Without final diagnosis of radiographically-confirmed CAP 551 1676 (20.4%) 280 (12.7%) 445 (12.5%) 101 (10.2%) 3053 (19.6%)
Received pneumococcal vaccine within 30 days before consent 193 (2.3%) 64 (2.9%) 168 (4.7%) 30 (3.0%) 455 (2.9%)
UAD population 22 7400 (89.9%) 2191 (99.1%) 3552 (99.4%) 984 (98.9%) 14,149 (90.9%)
UAD assay CAP subpopulation 6344 (77.0%) 1860 (84.2%) 2973 (83.2%) 866 (87.0%) 12,043 (77.3%)
Microbiology culture population 7 6741 (81.9%) 2043 (92.4%) 3223 (90.2%) 915 (92.0%) 12,929 (83.0%)
Microbiology culture CAP subpopulation 5993 (72.8%) 1775 (80.3%) 2791 (78.1%) 823 (82.7%) 11,382 (73.1%)
BinaxNOW population 22 7404 (89.9%) 2195 (99.3%) 3555 (99.5%) 986 (99.1%) 14,162 (90.9%)
BinaxNOW assay CAP subpopulation 6347 (77.1%) 1864 (84.3%) 2976 (83.3%) 868 (87.2%) 12,055 (77.4%)
Note: ’Unknown’ included 13 participants from Site 1029 as the IRB did not allow further info entered into database if participants are not eligible; the remaining ’Unknown’
were patients with medical history information (for risk condition) missing. High-risk = chronic kidney disease including end-stage renal disease (ESRD), organ transplan-
tation, immunodeficiency, hematologic cancer/malignancy, solid tumor cancer/malignancy, acquired immunodeficiency syndrome (AIDS), HIV, or immunosuppressive drug
therapy; at-risk = were not immunocompromised and had any of the following medical conditions: asthma, congestive heart failure, liver disease, chronic obstructive
pulmonary disease (COPD), diabetes mellitus, current smoking, or alcohol abuse; low-risk = participants who were not categorized as ‘‘high-risk” or ‘‘at-risk” were considered
‘‘low-risk”.
SP+ = Streptococcus pneumoniae positive; SP = Streptococcus pneumoniae negative; CAP = community acquired pneumonia; UAD = urinary antigen detection assay.
a The count for this row is used as denominators for percentages.
b Participant may be excluded for multiple reasons.
R.E. Isturiz et al. / Vaccine 37 (2019) 3352–3361 3355
4. Discussion
This is the largest prospective multicenter surveillance study
conducted to date in the United States to estimate the burden of
CAP due to PCV13 pneumococcal serotypes. Among 12,055
patients with CXR+CAP, 9.9% had S. pneumoniae detected—almost
half of which were attributable to PCV13 serotypes (4.6%). The
most commonly identified serotypes were 19A, 3, 5, 7F, and 6A,
all of which are contained in PCV13 but not in PCV7. At the time
of this study, however, a serotype-specific UAD assay did not exist
for the other non-PCV13 serotypes. Thus, given the higher sensitiv-
ity of the UAD for detecting pneumococcal serotypes compared to
BinaxNOW and traditional culture methods [17,34], this study
likely underestimates the proportion of CAP due to all pneumococ-
cus and overestimates the proportion of pneumococcal disease due
to PCV13 serotypes.
Table 2
Demographics by age and risk conditions for those with CAP, n = 12,055.
Age/risk group
65 (N = 6347) 18–64 high-risk (N = 1864) 18–64 at-risk (N = 2976) 18–64 low-risk (N = 868) Total (N = 12055)
Age at consent (years)
N 6347 1864 2976 868 12,055
Mean (SD) 76.7 (8.15) 51.9 (10.34) 50.1 (11.22) 45.3 (13.17) 64.1 (16.61)
Median 76 55 53 47 65
Range 65, 103 18, 64 18, 64 18, 64 18, 103
Sex
Female 3149 (49.6%) 934 (50.1%) 1560 (52.4%) 445 (51.3%) 6088 (50.5%)
Male 3198 (50.4%) 930 (49.9%) 1416 (47.6%) 423 (48.7%) 5967 (49.5%)
Race
White 5551 (87.5%) 1302 (69.8%) 2138 (71.8%) 659 (75.9%) 9650 (80.0%)
Black 765 (12.1%) 541 (29.0%) 809 (27.2%) 195 (22.5%) 2310 (19.2%)
Asian 25 (0.4%) 17 (0.9%) 13 (0.4%) 7 (0.8%) 62 (0.5%)
Other 6 (0.1%) 4 (0.2%) 16 (0.5%) 7 (0.8%) 33 (0.3%)
Ethnicity
Not Hispanic/Latino 6288 (99.1%) 1830 (98.2%) 2915 (98.0%) 828 (95.4%) 11,861 (98.4%)
Hispanic/Latino 58 (0.9%) 34 (1.8%) 60 (2.0%) 39 (4.5%) 191 (1.6%)
Missing 1 (0.0%) 0 (0%) 1 (0.0%) 1 (0.1%) 3 (0.0%)
Height (cm)
N 6334 1860 2968 861 12,023
Mean (SD) 168.7 (11.02) 169.9 (10.91) 169.9 (10.82) 170.6 (11.29) 169.3 (10.99)
Median 168 170 170 170.18 170
Min, Max 91, 213 119, 206 116, 198.12 91, 208.3 91, 213
Weight (kg)
N 6345 1863 2975 863 12,046
Mean (SD) 77.9 (22.41) 83.2 (26.04) 89.2 (28.79) 87.4 (28.48) 82.2 (25.62)
Median 75 79.4 84.2 83.14 78.4
Min, Max 29.6, 226.8 29.4, 226.9 30.3, 261.27 25.5, 284 25.5, 284
BMI (kg/m2)
N 6334 1860 2968 860 12,022
Mean (SD) 27.3 (7.52) 28.9 (8.97) 30.9 (9.73) 30.0 (9.37) 28.6 (8.61)
Median 26.175 27.35 29.26 28.535 27.17
Min, Max 11.73, 106.47 12.19, 81.33 11.11, 106.84 8.58, 91.35 8.58, 106.84
Previous enrollment in this study
Yes 714 (11.2%) 218 (11.7%) 262 (8.8%) 29 (3.3%) 1223 (10.1%)
No 5632 (88.7%) 1644 (88.2%) 2714 (91.2%) 839 (96.7%) 10,829 (89.8%)
Unknown 1 (0.0%) 2 (0.1%) 0 (0%) 0 (0%) 3 (0.0%)
Participant resides in the surveillance area
Yes 4895 (77.1%) 1402 (75.2%) 2352 (79.0%) 634 (73.0%) 9283 (77.0%)
No 1172 (18.5%) 372 (20.0%) 455 (15.3%) 151 (17.4%) 2150 (17.8%)
Missing 280 (4.4%) 90 (4.8%) 169 (5.7%) 83 (9.6%) 622 (5.2%)
Pneumonia Severity Index (PSI)
N 6250 1836 2937 856 11,879
Mean (SD) 110.2 (33.85) 86.9 (41.77) 60.6 (41.86) 43.3 (38.47) 89.5 (44.70)
Median 106 88 62 50 90
Min, Max 0, 264 0, 244 0, 230 0, 173 0, 264
PSI grade
GRADE I 22 (0.3%) 159 (8.5%) 651 (21.9%) 309 (35.6%) 1141 (9.5%)
GRADE II 560 (8.8%) 397 (21.3%) 1113 (37.4%) 348 (40.1%) 2418 (20.1%)
GRADE III 1377 (21.7%) 417 (22.4%) 530 (17.8%) 115 (13.2%) 2439 (20.2%)
GRADE IV 2764 (43.5%) 626 (33.6%) 501 (16.8%) 68 (7.8%) 3959 (32.8%)
GRADE V 1527 (24.1%) 237 (12.7%) 142 (4.8%) 16 (1.8%) 1922 (15.9%)
Missing 97 (1.5%) 28 (1.5%) 39 (1.3%) 12 (1.4%) 176 (1.5%)
Note: SD = standard deviation. High-risk = chronic kidney disease including end-stage renal disease (ESRD), organ transplantation, immunodeficiency, hematologic
cancer/malignancy, solid tumor cancer/malignancy, acquired immunodeficiency syndrome (AIDS), HIV, or immunosuppressive drug therapy; at-risk = were not immuno-
compromised and had any of the following medical conditions: asthma, congestive heart failure, liver disease, chronic obstructive pulmonary disease (COPD), diabetes
mellitus, current smoking, or alcohol abuse; low-risk = participants who were not categorized as ‘‘high-risk” or ‘‘at-risk” were considered ‘‘low-risk”.
BMI = body mass index; PSI = pneumonia severity index.
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The prevalence of S. pneumoniae has long been underestimated
in patients diagnosed with CAP, especially non-bacteremic pneu-
mococcal CAP, due to a lack of sensitive diagnostic assays [36].
Our study utilized traditional culture, BinaxNOW, and a serotype-
specific UAD assay designed to identify PCV13 serotypes that
may have been missed utilizing traditional culture or a qualitative
urinary antigen test. Importantly, nearly a third of all pneumococ-
cal CXR+CAP was detected only by UAD in our study, and UAD
allowed for the detection of an additional 345 cases of S. pneumo-
niae that would have otherwise been missed using traditional
detection methods only (BinaxNOW and culture).
Similar results were found in the Etiology of Pneumonia in the
Community (EPIC) study, conducted between 2010 and 2012 to
determine the etiology and incidence of CAP among 2488 adults
in the United States [28]. The original EPIC study utilized culture
and BinaxNOW urine testing, and showed that S. pneumoniae was
detected in only 5.0% of adults with radiographically confirmed
pneumonia. More recent data from a sub-study of EPIC, however,
has since been published (utilizing residual urine samples) and
showed that many cases of pneumococcal CAP were missed by tra-
ditional detection methods. Specifically, after utilizing the
serotype-specific UAD assay, the EPIC sub-study showed, that
9.7% and 6.3% of hospitalized CAP in adults was due to S. pneumo-
niae and PCV13 serotypes, respectively [37]. This represented a
near doubling of the original number of S. pneumoniae detections
in the early EPIC publication where the UAD was not incorporated.
It should be noted that the EPIC sub-study reported data that was
originally gathered from January 2010 through June 2012 [28].
These data were therefore obtained prior to the full impact of tran-
sitioning the pediatric immunization program from PCV7 to PCV13
in 2010. The data also preceded the 2014 ACIP recommendation for
adults aged 65 years.
The prevalence of S. pneumoniae observed in the current study
is lower than previously reported in a study by Sherwin et al.
[38]. In that study, which enrolled participants between 2010
and 2011, S. pneumoniae and PCV13 serotypes were detected in
13.8% and 11.0% of CAP cases, respectively, using several diagnostic
methods, including the same proprietary UAD assay used in the
current study [29,38]. The lower rates of PCV13 serotype disease
(roughly 5%) in our study is not unexpected, however, given that
more years of indirect effects stemming from the pediatric
PCV13 program had occurred during our study period. In addition,
the more recent decline in PCV13 serotypes seen in our study may
reflect the effectiveness of direct vaccination of adults aged
65 years.
Despite pediatric herd effects, PCV13 serotypes continue to
cause CAP in adults in the United States. A small but consistent
decline in PCV13 serotypes was observed over the three-year study
period (5.3% in year one to 3.9% in year three), which was driven by
PCV13-type reductions in the two adult populations who are rec-
ommended to receive PCV13 (i.e., adults aged 65 years and aged
<65 years with high-risk conditions). Only immunocompromised
Culture only
(n=122)
Culture and BinaxNOW
(n=78)
BinaxNOW only
(n=447)
UAD and BinaxNOW
(n=140)
UAD and culture
(n=28)
UAD only
(n=345)
UAD, culture, 
and BinaxNOW
(n=34)
Fig. 1. S. pneumoniae identification by diagnostic method among all study participants with radiographically-confirmed CAP, n = 1194. UAD = proprietary serotype-specific
urinary antigen detection assay. A total of 1194/12,055 (9.9%) had S. pneumoniae detected by any method. The UAD only detects serotypes contained in 13-valent
pneumococcal conjugate vaccine.
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adults aged19 years were recommended to receive PCV13 during
the entire study period, and PCV13 uptake in this population is
around 20–25% [39]. During the course of our study (in September
2014), ACIP recommended routine use of PCV13 for all adults aged
65 years, with PCV13 uptake steadily increasing in this popula-
tion during the remainder of our study period [40,41]. Interest-
ingly, in adults aged <65 years with at-risk or low-risk
conditions, where PCV13 is not used, no decline in PCV13 sero-
types was observed over the current study period. Given that indi-
rect effects should affect all populations equally, this implies that
(1) there may be an additional reduction in PCV13 serotypes in
vaccinated adult populations and (2) PCV13-type CAP may have
reached a plateau (e.g., between 5% and 6% in adults aged <65 years
with at-risk conditions) in adult populations where PCV13 is not
used. These findings were recently confirmed in a time-trend anal-
ysis [42], however, teasing apart the impact of adult PCV13 use
Table 3
Distribution of pneumococcal serotypes identified from CAP cases by UAD or culture, n = 12,055.
Age/risk group
65n (%) 18 to 64 high-risk n (%) 18 to 64 at-risk n (%) 18 to 64 low-risk n (%) Total n (%)
Total populationa (Denominator for % participants) 6347 1864 2976 868 12,055
SP + by UAD or culture 350 (5.5%) 134 (7.2%) 214 (7.2%) 49 (5.6%) 747 (6.2%)
SP + isolates not serotypedb 21 (0.3%) 8 (0.4%) 15 (0.5%) 3 (0.3%) 47 (0.4%)
SP + with serotypesc 336 (5.3%) 128 (6.9%) 202 (6.8%) 47 (5.4%) 713 (5.9%)
Serotypes covered by PCV13c 265 (4.2%) 95 (5.1%) 159 (5.3%) 33 (3.8%) 552 (4.6%)
Serotypes covered by PCV7 53 (0.8%) 37 (2.0%) 31 (1.0%) 3 (0.3%) 124 (1.0%)
4 8 (0.1%) 2 (0.1%) 2 (0.1%) 0 (0.0%) 12 (0.1%)
6B 2 (0.0%) 4 (0.2%) 0 (0.0%) 0 (0.0%) 6 (0.0%)
9V 5 (0.1%) 6 (0.3%) 4 (0.1%) 0 (0.0%) 15 (0.1%)
14 11 (0.2%) 6 (0.3%) 8 (0.3%) 1 (0.1%) 26 (0.2%)
18C 6 (0.1%) 7 (0.4%) 9 (0.3%) 0 (0.0%) 22 (0.2%)
19F 10 (0.2%) 5 (0.3%) 3 (0.1%) 1 (0.1%) 19 (0.2%)
23F 12 (0.2%) 9 (0.5%) 7 (0.2%) 1 (0.1%) 29 (0.2%)
Additional 6 serotypes covered by PCV13 222 (3.5%) 69 (3.7%) 136 (4.6%) 31 (3.6%) 458 (3.8%)
1 15 (0.2%) 5 (0.3%) 4 (0.1%) 5 (0.6%) 29 (0.2%)
3 57 (0.9%) 21 (1.1%) 41 (1.4%) 11 (1.3%) 130 (1.1%)
5 36 (0.6%) 11 (0.6%) 30 (1.0%) 1 (0.1%) 78 (0.6%)
6A 29 (0.5%) 3 (0.2%) 13 (0.4%) 2 (0.2%) 47 (0.4%)
7F 24 (0.4%) 8 (0.4%) 18 (0.6%) 4 (0.5%) 54 (0.4%)
19A 73 (1.2%) 25 (1.3%) 46 (1.5%) 8 (0.9%) 152 (1.3%)
Serotypes NOT covered by PCV13b 77 (1.2%) 35 (1.9%) 46 (1.5%) 15 (1.7%) 173 (1.4%)
10A 1 (0.0%) 0 (0.0%) 1 (0.0%) 1 (0.1%) 3 (0.0%)
11A 9 (0.1%) 2 (0.1%) 2 (0.1%) 0 (0.0%) 13 (0.1%)
11C 0 (0.0%) 0 (0.0%) 1 (0.0%) 0 (0.0%) 1 (0.0%)
12F 3 (0.0%) 4 (0.2%) 2 (0.1%) 0 (0.0%) 9 (0.1%)
13 1 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.0%)
15A 7 (0.1%) 0 (0.0%) 2 (0.1%) 0 (0.0%) 9 (0.1%)
15B 0 (0.0%) 1 (0.1%) 0 (0.0%) 2 (0.2%) 3 (0.0%)
15C 0 (0.0%) 1 (0.1%) 0 (0.0%) 0 (0.0%) 1 (0.0%)
16F 6 (0.1%) 2 (0.1%) 5 (0.2%) 0 (0.0%) 13 (0.1%)
17F 3 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (0.0%)
20 2 (0.0%) 0 (0.0%) 4 (0.1%) 2 (0.2%) 8 (0.1%)
21 3 (0.0%) 3 (0.2%) 0 (0.0%) 0 (0.0%) 6 (0.0%)
22F 10 (0.2%) 8 (0.4%) 5 (0.2%) 5 (0.6%) 28 (0.2%)
23A 1 (0.0%) 0 (0.0%) 1 (0.0%) 0 (0.0%) 2 (0.0%)
23B 4 (0.1%) 1 (0.1%) 2 (0.1%) 0 (0.0%) 7 (0.1%)
25F 0 (0.0%) 1 (0.1%) 0 (0.0%) 0 (0.0%) 1 (0.0%)
31 2 (0.0%) 0 (0.0%) 1 (0.0%) 0 (0.0%) 3 (0.0%)
33F 3 (0.0%) 1 (0.1%) 5 (0.2%) 0 (0.0%) 9 (0.1%)
34 2 (0.0%) 1 (0.1%) 2 (0.1%) 1 (0.1%) 6 (0.0%)
35B 5 (0.1%) 1 (0.1%) 3 (0.1%) 0 (0.0%) 9 (0.1%)
38 1 (0.0%) 0 (0.0%) 1 (0.0%) 0 (0.0%) 2 (0.0%)
6C 8 (0.1%) 2 (0.1%) 5 (0.2%) 0 (0.0%) 15 (0.1%)
7B 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.1%) 1 (0.0%)
7C 0 (0.0%) 2 (0.1%) 1 (0.0%) 0 (0.0%) 3 (0.0%)
8 3 (0.0%) 2 (0.1%) 1 (0.0%) 3 (0.3%) 9 (0.1%)
9N 3 (0.0%) 3 (0.2%) 2 (0.1%) 0 (0.0%) 8 (0.1%)
Serotypes covered by PPSV23c 273 (4.3%) 113 (6.1%) 169 (5.7%) 44 (5.1%) 599 (5.0%)
Note: high-risk = chronic kidney disease including end-stage renal disease (ESRD), organ transplantation, immunodeficiency, hematologic cancer/malignancy, solid tumor
cancer/malignancy, acquired immunodeficiency syndrome (AIDS), HIV, or immunosuppressive drug therapy; at-risk = were not immunocompromised and had any of the
following medical conditions: asthma, congestive heart failure, liver disease, chronic obstructive pulmonary disease (COPD), diabetes mellitus, current smoking, or alcohol
abuse; low-risk = participants who were not categorized as ‘‘high-risk” or ‘‘at-risk” were considered ‘‘low-risk”.
UAD = urinary antigen detection assay; SP+ = Streptococcus pneumoniae positive; SP- = Streptococcus pneumoniae negative; CAP = community acquired pneumonia; PCV7 = 7-
valent pneumococcal conjugate vaccine; PCV13 = 13-valent pneumococcal conjugate vaccine; PPSN23 = 23-valent pneumococcal polysaccharide vaccine.
a Number of participants included in the population, with non-missing UAD/Culture results. The values in this row are used as the denominators for percentage of
participants.
b From culture only. Only one isolate is considered as ’Not Serotyped’ if participants had none SP + isolates serotyped. The remaining isolates will NOT be considered as ’Not
Serotyped’ if at least one SP + isolate were serotyped.
c From culture or UAD.
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from continued indirect effects stemming from the pediatric vacci-
nation program remains difficult and warrants future research.
Our data describing the proportion of CAP in adults that
remains PCV13-type are important when viewed in the context
of the overall burden of all-cause CAP in the United States. Ramirez
et al recently published a prospective, population-based study that
demonstrated the incidence of CAP was roughly 700 per 100,000
among adults aged 18 years—which is higher than has been pre-
viously estimated. The authors showed that, when extrapolated to
the population of the United States, this incidence rate corresponds
to approximately 1.7 million total adult hospitalizations per year
for CAP [43]. Based on this recently-published CAP burden [43],
the roughly 4–5% of all CAP that remains PCV13-type observed in
our current study translates to thousands of potentially-
preventable hospitalizations in adults each year—the large major-
ity of which occurs in adults aged  65 years or aged <65 years
with underlying chronic medical conditions where the overall inci-
dence rate of CAP is at least 1000–2000 per 100,000 per year [43].
Patients with underlying comorbidities are at increased risk for
developing pneumonia including pneumococcal pneumonia [44]
and older adults surviving CAP experience a long recovery period
[45]. Ramirez et al. showed that patients who had diabetes, chronic
heart failure, or chronic obstructive pulmonary disease had three
to nine times higher incidence of hospitalization compared to the
overall all-cause CAP population [43]. In a retrospective cohort
study conducted by Shea et al, rates of pneumococcal pneumonia
among at-risk adults were three times the rate in age-matched
healthy counterparts [44]. Notably, patients with COPD had pneu-
monia rates that were eight to nine times higher compared to
heathy counterparts [44]. Patients enrolled in our study had
numerous underlying conditions placing them at increased risk
of pneumonia. Most patients (86%) with CXR+CAP had at least
one high-risk or at-risk condition, predominately COPD (43%).
Thirty-day all-cause mortality in our population was approxi-
mately 9% in patients with CXR+CAP, similar to previous reports
[43,46].
Our study has several limitations. First, most participants (80%)
were from the Louisville sites. Despite having other sites from
across the country to enroll patients, this high proportion of
patients recruited from this one city limits the generalizability of
the results. Second, study start-up was staggered, and recruitment
varied considerably among sites and over time. Third, the study
began approximately one year prior to the September 2014 ACIP
recommendation of PCV13 for adults aged 65 years. Uptake of
PCV13 in this population after the recommendation was slow
and the impact of direct vaccination in this population is unclear.
Fourth, detection of pneumococcal serotypes by the UAD assay is
limited to detection of only the serotypes contained in the PCV13
vaccine.
Despite its limitations, our study demonstrates that despite the
success of a national pediatric immunization program (since 2010
for PCV13), residual PCV13 serotype disease remains in adults.
Moreover, our results suggest that this persistent disease burden
has been grossly underestimated by previous studies that used
only traditional pneumococcal detection methods and did not
include a serotype-specific UAD. Given this remaining vaccine-
type disease identified in adults, direct vaccination with PCV13 is
likely beneficial in all older adults and younger adults with under-
lying chronic conditions. Our data support the appropriateness of
current ACIP recommendations, which include routine pneumo-
coccal vaccination in all adults aged 65 years and younger adults
with high-risk medical conditions. These recommendations are
rooted in the fact that, although the overall prevalence has
declined, PCV13 serotype disease remains and the potential
public-health benefit of continued PCV13 vaccination in the adult
population remains substantial.
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Fig. 2. Percentage of CAP caused by PCV13 serotypes over time by age/risk group among US adults, n = 12,055. CAP = community-acquired pneumonia; PCV13 = 13-valent
pneumococcal conjugate vaccine. Dotted lines represent declines between year one and year three that were statistically significant at P < .05. High-risk = chronic kidney
disease including end-stage renal disease (ESRD), organ transplantation, immunodeficiency, hematologic cancer/malignancy, solid tumor cancer/malignancy, acquired
immunodeficiency syndrome (AIDS), HIV, or immunosuppressive drug therapy; at-risk = were not immunocompromised and had any of the following medical conditions:
asthma, congestive heart failure, liver disease, chronic obstructive pulmonary disease (COPD), diabetes mellitus, current smoking, or alcohol abuse; low-risk = participants
who were not categorized as ‘‘high-risk” or ‘‘at-risk” were considered ‘‘low-risk”.
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